Business Wire

GlobalLogic Launches Women Influencers Program to Promote Diverse Leadership Development

11.5.2022 15:00:00 EEST | Business Wire | Press release

Share

GlobalLogic Inc., a Hitachi Group company and leader in Digital Engineering, has launched the Women Influencers Program, designed to encourage and enable women employees interested in exploring cross-functional management positions within the technology firm. As part of the company’s focus on DEI (Diversity, Equity, Inclusion), GlobalLogic is aiming for greater diversity at all levels in the workforce across gender, sexual orientation, color, ethnic origin, age and ability. The Women Influencers Program is specifically focused to promote greater gender diversity especially among the company’s leadership ranks. The Program will provide developmental and mentoring opportunities through GlobalLogic’s People Development function and individual business units.

Core Program Elements

The Program centers around nine competencies that participants will explore via a set of learning modules, with an entire Program journey expected to last five to six months. Operating in tandem, global cohorts of women based across the globe will join together to share and learn from collective experiences.

The competencies promote the development of “soft” skills – meaning those not directly tied to a formal educational program but rather gained through experience and from peers. These competencies include directness and candor, inspiring and influencing others, effective decision making, professional network development, and the continued development of communication skills. Program participants will also receive training specific to GlobalLogic’s capabilities which are meant to enhance essential corporate knowledge and increase depth of technical competencies.

"Diversity, equity, and inclusion are paramount to GlobalLogic's success," said Amy Hanlon-Rodemich, Chief People Officer, GlobalLogic. "We created the Women Influencers Program to elevate emerging women leaders and to prepare them to take on a wider range of roles and responsibilities including expansion into senior leadership roles. This Program will enable more women leaders to take on more strategic positions within the company."

Based on Research

Initially piloted in India in 2020, the Program’s intent was to actively focus on enhancing the company’s management pipeline with a consideration toward diversity and inclusivity; particularly for women within the company. Upon conducting in-depth analysis of leadership roles and paths to those positions, GlobalLogic’s Program development team discovered that while the digital engineering firm’s overall diversity stats were above the industry average, an even more diverse senior management team would be a tremendous enhancement to the current management ranks.

Research suggests that the female-to-male disparity is due to multiple factors, including prioritization of personal and family life, cultural demands and differences, and organizational dynamics. It was also noted that many women express a distinct “burn out” effect, indicating an ongoing struggle to identify resources and opportunities for progressing their careers.

In response, the Program development team explored options for accelerating women’s career paths by developing essential leadership skills and helping them becoming future ready, positioning participants to take on new roles within GlobalLogic.

“Our aim is to correct the imbalance in women holding leadership roles versus men, which is common throughout the technology industry according to global statistics,” said Shivani Khanna, Senior Manager, People Team, GlobalLogic. “We believe that through our Program’s structured guidance and encouragement, we can positively shift that dynamic.”

Establishing a Supportive Ecosystem

The ecosystem being developed by GlobalLogic will include “Anchors,” a role held by members of the human resources team who will help ensure that the Program is operating effectively. Anchors will also manage the learning and mentor groups that will spearhead the specific activities designed to provide the professional skills previously referenced.

Participants’ managers will be enlisted as “Program Catalysts” responsible for ensuring that the Program is not simply a training exercise but rather a complete learning journey championing employee learning and advancement across the organization.

“Program Sponsors — the managers and mentors — will act as coaches overseeing the employees’ journeys. They will help steer participants toward the content and activities appropriate to each individual’s unique path,” Khanna continued. “We’re excited to officially launch this Program in GlobalLogic locations around the world.”

About GlobalLogic

GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

GlobalLogic, Inc. (Global)
Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye